Novartis revenues 2007-2023

In 2023, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to 45.5 billion U.S. dollars. This is a decrease of five billion U.S. dollars compared to the year before. The reason is the spin-off of Novartis' Sandoz segment during mid-2023.

Novartis’ revenue by segment

Between 2014 and 2023, the multinational corporation, based in Basel, Switzerland, generated the bulk of its revenue through brand name pharmaceuticals: in 2023, the company made 31.8 billion U.S. dollars from this segment. In the same year Novartis spun off its generic drug division Sandoz.

Competitor Sanofi

Another global leader in the world of healthcare and pharmaceuticals is Sanofi, which is based in Paris, France. In 2022, the French company generated 43 billion euros' worth of revenue. That same year, the majority of Sanofi’s revenue was earned through pharmaceuticals (30.7 billion euros), while the vaccine business segment generated 7.2 billion euros.

Novartis AG's total revenue from 2007 to 2023 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2024

More information

Region

Worldwide

Survey time period

2007 to 2023

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015.
** During this year, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included.

*** Reduced revenue due to Sandoz spin-off.

Open this statistic in...

French

Citation formats